The Initial Human Atherosclerotic Lesion and Lipoprotein Modification-A Deep Connection

Area of Science:

• Cardiovascular Research
• Molecular Biology
• Pathophysiology

Background:

• Atherosclerosis research often overlooks prelesional stages, missing crucial insights into disease triggers.
• Native Low Density Lipoproteins (LDL) are not inherently inflammatory; modification is required for atherogenicity.
• Early events like extracellular lipoprotein deposition precede foam cell formation and lesion development.

Purpose of the Study:

• To investigate the role of early, prelesional stages in atherogenesis.
• To explore the concept of enzymatically modified LDL (eLDL) as a primary atherogenic factor.
• To evaluate strategies for preventing or reversing initial atherosclerotic lesions.

Main Methods:

• Review and synthesis of existing evidence on atherogenesis, focusing on lipoprotein modification.
• Analysis of hypotheses related to LDL modification, inflammation, and immune system involvement.
• Consideration of therapeutic strategies targeting lipoprotein metabolism and enzyme regulation.

Main Results:

• Evidence supports LDL modification by hydrolytic enzymes (eLDL) as a key step, preceding inflammation.
• Initiation of atherosclerosis may involve macrophage uptake and reverse transport of eLDL without initial inflammation.
• Lowering plasma levels of atherogenic lipoproteins remains a cornerstone therapy, aligning with the retention hypothesis.

Conclusions:

• Preventing or reversing early atherosclerotic lesions is crucial for averting clinical manifestations.
• Targeting enzymes responsible for LDL modification presents a promising pharmacological research avenue.
• While anti-inflammatory therapies may be adjuvant, lowering atherogenic lipoproteins is essential for atherosclerosis management.